维普期刊资源整合服务平台（V6.5）

146篇 您的检索式：作者名="SALTZ L"

选中清除导出查看参考文献查看引证文献引用追踪共8页首页上一页第1页下一页末页 /8 跳转

	题名	作者	年代	出处	被引量
1	Bevacizumab in combination with oxaliplatin - based chemotherapy as first - line therapy in metastatic colorectal cancer: a randomized phase Ⅲ study显示文摘	SALTZ L B CLARKE S DIAZ -RUBIO E	2008	J Clin Oncol2008，26，12：	1
2	Panitumumab 显示文摘	SALTZ L EASLEY C KIRKPATRICK P	2006	Nat Rev Drug Discov2006，5，12：	1
3	Phase Ⅱ trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor显示文摘	SALTZ L B MEROPOL N J LOEHRER P J Sr	2004	J Clin Oncol2004，22，7：	1
4	Randomized phase Ⅱ trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study显示文摘	SALTZ L B LENZ H J KINDLER H L	2007	J Clin Oncol2007，25，29：	1
5	Cutaneous adverse effects with HER1/EGFR - targeted agents: is there a silver lining 显示文摘	Perez -Soler R Saltz L	2005	J Clin Oncol2005，23，22：	1
6	NCCN Clinical Practice Guidelines in Oncology:rectal cancer 显示文摘	Engstrom PF Arnoletti JP Benson AB 3rd Chen YJ Choti MA Cooper HS Covey A Dilawari RA Early DS Enzinger PC Fakih MG Fleshman J Jr Fuchs C Greta JL Kiel K Knol JA Leong LA Lin E Mulcahy MF Rao S Ryan DP Saltz L Shibata D Skibber JM Sofocleous C Thomas J Venook AP Willett C	2009	J Natl Compr Canc Netw2009，7，：	1
7	A phase Ⅱ trial of pleurectomy/decortications followed by intraplearal and systemic chemotherapy for malignant pleural mesothelioma显示文摘	Ruseh V Saltz L Venkatrarnan E	1994	J Clin Oncol1994，12，：	1
8	Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor显示文摘	Saltz L Meropol NJ		0，，：	1
9	Phase II trial of cetuximab in patients with refraetory colorectal cancer that expresses the epidermal growth factor receptor显示文摘	Saltz L B Meropol N J Loehrer P J	2004	J Clin Oncol2004，22，7：	1
10	Phase II trial of Cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor显示文摘	SALTZ L B MEROPOL N J LOEHRER Sr P J	2004	J Clin Oncol2004，22，7：	1
11	Phase Ⅱ trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor显示文摘	Saltz L Meropol N Loehrer P	2004	J Clin Oncol2004，22，7：	1
12	The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor 显示文摘	HOLEN K SALTZ L B HOLLYWOOD E	2008	Investigational New Drugs2008，26，1：	1
13	Cutaneous adverse effects with HER1/EGFR targeted agents:is there a silver lining显示文摘	PEREZ-SOLER R SALTZ L	2005	J Clin Oncol2005，23，22：	1
14	Randomizde phase Ⅱ trial of cetuximab/bevacizumab/irinotecan(CBI)in irinotecan refractory colorectal cancer显示文摘	Saltz L Lenz H-J Hochster H	2005	J Clin Oncol2005，23，16：	1
15	Cutaneous adverse effects with HER1/ EGFR-targeted agents:is there a silver lining 显示文摘	Per6z-Solert R Saltz L	2005	J Clin Oncol2005，23，22：	1
16	Cutaneous adverse effects with HER1/EGFR-targeted agents:is there a silver lining显示文摘	Perez-Soler R Saltz L	2005	J Clin Oncol2005，23，22：	1
17	Cutaneous adverse effects with HER1/EGFR-targeted agents : is there a silver lining显示文摘	Perez-Soler R Saltz L	2005	J Clin Oncol2005，23，22：	1
18	lrinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer显示文摘	Saltz L B Cox J V Blanke C	2000	N Engl J Med2000，343，13：	1
19	Cutaneous adverse effects with HER1/ EGFR-targeted agents: is there a silver lining? 显示文摘	Perez-Soler R Saltz L	2005	J Clin Oncol2005，23，22：	1
20	Phase II study of the eyclin- dependent kinase inhibitor flavopifidol administered to patients with advanced gastric carcinoma显示文摘	Schwartz GK Ilson D Saltz L	2001	J Clin Oncol2001，19，7：	1

返回顶部每页显示：

共8页首页上一页第1页下一页末页 /8 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示